Aker BioMarine

Regulatory Filings • Aug 10, 2023

Aker BioMarine has received approval for LYSOVETA™ as a new dietary ingredient in the US

Aker BioMarine has received approval for LYSOVETA™ as a new dietary ingredient in the US

Aker BioMarine was recently informed that LYSOVETA™, the company’s innovative brain and eye health ingredient derived from krill, has received the necessary regulatory approval for commercial launch as a dietary supplement in the US.

LYSOVETA™ is a dietary supplement featuring essential nutrients such as choline and Omega 3 in the form of Lysophosphatidylcholine (LPC). LPC is a molecule with the unique ability to be transported across the blood brain barrier containing important nutrients for the brain and eye health.

The company is working with well-established brands to drive commercial opportunities for LYSOVETA™. Launching a new ingredient involves long processes, starting from client testing & trial and going all the way to retailer sales & marketing efforts, but the company has an ambition to have first sales of consumer products during 2024.

Production of LYSOVETA™ is done in the company’s manufacturing plant in Houston, which has a dedicated production line up and running.

For further information, please contact

Christopher Robin Vinter, Investor Relations

Mobile: +47 911 60 820

Email: Christopher.vinter@akerbiomarine.com

About Aker BioMarine:

Aker BioMarine is an Antarctic krill-harvesting company and leading biotech innovator developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.